Mercer Global Advisors Inc. ADV Acquires New Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Mercer Global Advisors Inc. ADV acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,606 shares of the medical equipment provider’s stock, valued at approximately $209,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Daiwa Securities Group Inc. purchased a new position in Lantheus in the first quarter valued at about $1,269,000. Nordea Investment Management AB increased its holdings in Lantheus by 42.6% in the first quarter. Nordea Investment Management AB now owns 47,322 shares of the medical equipment provider’s stock valued at $2,932,000 after buying an additional 14,147 shares in the last quarter. Hancock Whitney Corp increased its holdings in Lantheus by 265.6% in the first quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock valued at $1,254,000 after buying an additional 14,639 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new position in Lantheus in the second quarter valued at about $290,000. Finally, Pitcairn Co. increased its stake in shares of Lantheus by 117.0% during the 1st quarter. Pitcairn Co. now owns 8,364 shares of the medical equipment provider’s stock worth $521,000 after purchasing an additional 4,509 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Down 3.6 %

Shares of LNTH opened at $105.84 on Wednesday. The firm has a market cap of $7.34 billion, a PE ratio of 16.16 and a beta of 0.50. The company’s fifty day moving average is $104.36 and its two-hundred day moving average is $86.40. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. During the same quarter in the previous year, the firm posted $1.40 EPS. The business’s revenue was up 22.5% compared to the same quarter last year. Analysts forecast that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

Insider Activity

In related news, Director Gary J. Pruden sold 12,530 shares of the stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total value of $1,190,851.20. Following the completion of the transaction, the director now owns 11,978 shares of the company’s stock, valued at $1,138,389.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Gary J. Pruden sold 12,530 shares of the company’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $95.04, for a total value of $1,190,851.20. Following the sale, the director now directly owns 11,978 shares of the company’s stock, valued at $1,138,389.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the transaction, the chief accounting officer now directly owns 62,216 shares of the company’s stock, valued at $7,661,900.40. The disclosure for this sale can be found here. Insiders sold 40,852 shares of company stock worth $3,922,001 over the last ninety days. Corporate insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

LNTH has been the subject of a number of recent research reports. B. Riley raised their price objective on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Leerink Partners raised their price objective on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, July 11th. Truist Financial dropped their price objective on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. JMP Securities dropped their price objective on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research note on Thursday, August 1st. Finally, Redburn Atlantic assumed coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $126.00.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.